Compare Moderna, Inc. (MRNA) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Motorola Solutions Inc — how do they compare? Moderna, Inc. trades at $218.64 (market cap $78.65B), while Motorola Solutions Inc trades at $443.56 (market cap $74.00B). The key difference: Moderna, Inc. and Motorola Solutions Inc are close in size by market cap, and Motorola Solutions Inc pays a 1.08% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Motorola Solutions Inc for 100 Days on average.
| MRNA | MSI | |
|---|---|---|
Market Cap | $78.65B | $74.00B |
Volume | 37,373,437 | 722,147 |
Sector | Health | Technology |
52-Week High | $203.46 | $491.24 |
52-Week Low | $22.36 | $363.83 |
Typical Hold Time | 59 Days | 100 Days |
Enterprise Value | $74.80B | $82.90B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Motorola Solutions (MSI) trades at $443.80, down 1.04% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and net income of $2.15B, supported by a record $15.6B backlog as of Q2 2026 (Zacks Investment Research, 2026-09-28). Recent acquisitions like D-Fend Solutions for $1.5B expand its security portfolio, while a new $2B share repurchase authorization signals confidence (Business Wire, 2026-09-09).
The outlook is positive with a consensus price target of $525.86, implying 18.5% upside, and 71% of analysts rate it a Buy. Risks include elevated debt levels with a debt-to-asset ratio of 47.29% in 2025 and negative net cash flow trends, but strong public safety contract wins and AI integration in video analytics provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
